ImprimisRx to Feature New Formulation and Poster Presentation on MKO Melt at AAO Meeting in Chicago

ImprimisRx announced its participation at the upcoming 2018 American Academy of Ophthalmology (AAO) annual meeting to be held at the McCormick Place Convention Center in Chicago, October 26-30. 

At the conference, attendees will have the opportunity to meet with ImprimisRx representatives in Booth #4254 to learn about Imprimis’s full portfolio of formulations, including a new tropicamide and phenylephrine combination topical offering from its FDA-registered 503B outsourcing facility. This formulation further expands the company’s office-use portfolio of ophthalmic focused compounded medications.

Maggie Jeffries, MD, a board-certified anesthesiologist, will be presenting a poster on Sunday October 28 at 12:45 pm at the conference. The poster titled “Conscious sedation efficacy of the novel medication, MKO Melt, during cataract surgery” will summarize the results of her investigator led 611-patient IRB approved prospective, controlled, randomized, three arm comparator study. The purpose of the study was to compare the conscious sedation efficacy of a non-opioid sublingual troche, Imprimis’s MKO Melt, to diazepam and a diazepam/tramadol/ondansetron combination during cataract surgery.

The MKO Melt (midazolam/ketamine/ondansetron) is a noninvasive, non-opioid, patented, sublingual troche used typically by physicians for short term procedures, with potentially 100 million addressable procedures in the U.S. annually across multiple verticals and a potential multi-billion-dollar opportunity. Imprimis Pharmaceuticals recently formed a new subsidiary, Melt Pharmaceuticals, which is pursuing the development of 505(b)(2) drug candidates for FDA approval based on the underlying technology of the MKO Melt.